Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene options rights to Abide's serine hydrolase program; could acquire the company; deal terminated

Executive Summary

Abide Therapeutics Inc. (developing drugs that target serine hydrolase enzymes) granted Celgene Corp. options to exclusively license rights to the start-up’s first two compounds that reach the clinic for immune diseases and inflammation. Celgene also has the option to acquire the company.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes M&A Option
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register